{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bansal N"],"funding":["NCATS","Michigan Institute for Clinical and Health Research","National Center for Research Resources","Clinical and Translational Science Collaborative of Cleveland","NCATS NIH HHS","Johns Hopkins University","NCRR NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases","University of Maryland","National Institutes of Health","National Center for Advancing Translational Sciences (NIH","NIH","NIDDK NIH HHS","University of Illinois at Chicago","Perelman School of Medicine at the University of Pennsylvania","Kaiser Permanente","Clinical and Translational Research in Cardiometabolic Diseases","NIGMS NIH HHS"],"pagination":["1598-1607"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6933450"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(11)"],"pubmed_abstract":["<h4>Introduction</h4>Assessment of impaired vitamin D metabolism is limited by lack of functional measures. CYP24A1-mediated vitamin D clearance, calculated as the ratio of serum 24,25-dihydroxyvitamin D3 to 25-hydroxyvitamin D3 (the vitamin D metabolic ratio, VDMR), is induced by 1,25-dihydroxyvitamin D and may assess tissue-level activity. We tested associations of the VDMR with risks of death and progression to end-stage renal disease (ESRD) in patients with chronic kidney disease (CKD).<h4>Methods</h4>We studied participants from the Chronic Renal Insufficiency Cohort (CRIC), which included a random subset of 1080 CRIC participants plus additional participants who experienced ESRD or died (case cohort study design). Serum 24,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 was measured "],"journal":["Kidney international reports"],"pubmed_title":["Vitamin D Metabolic Ratio and Risks of Death and CKD Progression."],"pmcid":["PMC6933450"],"funding_grant_id":["U01 DK061021","P20 GM109036","U01DK061028","U01 DK060990","U01 DK061022","UL1RR029879","M01 RR013987","UL1TR000433","GCRC M01 RR-16500","U01DK061021","U01 DK061028","UL1 RR029879","UL1 TR000433","U01DK060990","U01DK061022","UL1 TR000439","U24 DK060990","M01 RR016500","R01DK099199","U01 DK060902","UL1TR-000424","UL1 RR024131","U01DK060963","UL1TR000003","U01DK060984","UL1 TR000003","UL1RR-024131","U01DK060902","U01 DK060963","UL1 TR002548","UL1 TR000424","U01 DK060984","U01 DK060980","U01DK060980","R01 DK072231","UL1TR000439","R01 DK099199"],"pubmed_authors":["Feldman H","Isakova T","Kusek JW","Go AS","Xie D","Feldman HI","CRIC Study Investigators","Townsend RR","Rao PS","Robinson-Cohen C","de Boer IH","Lash JP","Wolf M","Zelnick L","He J","Katz R","Kusek J","Lash J","Rahman M","Hoofnagle A","Kestenbaum B","Denburg M","Appel LJ","Leonard M","Appel L","Bansal N"],"additional_accession":[]},"is_claimable":false,"name":"Vitamin D Metabolic Ratio and Risks of Death and CKD Progression.","description":"<h4>Introduction</h4>Assessment of impaired vitamin D metabolism is limited by lack of functional measures. CYP24A1-mediated vitamin D clearance, calculated as the ratio of serum 24,25-dihydroxyvitamin D3 to 25-hydroxyvitamin D3 (the vitamin D metabolic ratio, VDMR), is induced by 1,25-dihydroxyvitamin D and may assess tissue-level activity. We tested associations of the VDMR with risks of death and progression to end-stage renal disease (ESRD) in patients with chronic kidney disease (CKD).<h4>Methods</h4>We studied participants from the Chronic Renal Insufficiency Cohort (CRIC), which included a random subset of 1080 CRIC participants plus additional participants who experienced ESRD or died (case cohort study design). Serum 24,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 was measured ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Nov","modification":"2025-04-04T22:34:43.661Z","creation":"2020-05-22T01:18:34Z"},"accession":"S-EPMC6933450","cross_references":{"pubmed":["31891001"],"doi":["10.1016/j.ekir.2019.08.014"]}}